Arcus Bioscience Stock Price, News & Analysis

Arcus Biosciences reported its Q3 2022 financial results, revealing revenues of $33.6 million, up from $9.5 million in Q3 2021, driven by collaboration with Gilead. The company holds $1.2 billion in cash, sufficient to fund operations into 2026. Arcus is advancing its clinical pipeline, focusing on anti-TIGIT therapies with three Phase 3 trials for domvanalimab in lung cancer. A strategic amendment to the ARC-10 trial design now compares domvanalimab and zimberelimab to pembrolizumab, excluding a chemotherapy arm. The trial aims to define a new standard-of-care in NSCLC.

Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of options and restricted stock units to 14 new employees, totaling 35,200 shares at an exercise price of $26.15, the closing price on October 10, 2022. Additionally, 17,600 shares were awarded as restricted stock units. This award is part of the company’s 2020 Inducement Plan, which complies with NYSE regulations. Arcus focuses on developing innovative cancer therapies and has advanced six investigational medicines to clinical studies.

Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of stock options and restricted stock units to ten new employees, totaling 33,950 and 16,975 shares, respectively. The options were priced at $25.70, aligning with the closing price on September 8, 2022. This equity grant falls under the 2020 Inducement Plan, approved by the Board of Directors. Arcus is focused on developing innovative cancer therapies, with clinical studies underway for six investigational medicines targeting various biological pathways.

Arcus Biosciences (NYSE:RCUS) announced its participation in key investor conferences. The Citi 17th Annual BioPharma Conference will take place on September 7, 2022, in Boston, MA, featuring 1-on-1 meetings. Following this, the Morgan Stanley 20th Annual Global Healthcare Conference is scheduled for September 12, 2022, in New York, NY, with a fireside chat at 12:30 p.m. ET. A live webcast will be available on the Arcus website, with replays accessible afterward.

Arcus Biosciences, Inc. (NYSE:RCUS) announces the granting of stock options and restricted stock units to nine new employees. A total of 22,100 options were provided at an exercise price of $27.35, reflecting the closing price on August 8, 2022. Additionally, 11,050 restricted stock units were awarded. These grants are in accordance with the Company’s 2020 Inducement Plan, approved in January 2020, under NYSE Rule 303A.08. Arcus is focused on developing innovative cancer therapies and has advanced six investigational medicines into clinical studies.

Arcus Biosciences (NYSE:RCUS) appointed Dr. Dimitry S.A. Nuyten as Chief Medical Officer effective August 1, 2022. Dr. Nuyten will lead the clinical development organization, comprising nearly 200 employees and six clinical-stage programs, including four ongoing Phase 3 trials for domvanalimab in combination therapies targeting various cancers. His extensive background includes leadership roles at Nektar Therapeutics and Pfizer. Arcus aims to expedite the development of innovative cancer treatments through collaborations, notably with Gilead, which invested $200 million into the company in 2020.

Arcus Biosciences (NYSE: RCUS) reported its second-quarter financial results, revealing collaboration and license revenues of $26.8 million, up from $9.5 million year-over-year. The company's cash position stands strong at $1.3 billion, sufficient to fund operations into 2026. Notable updates include ongoing Phase 3 trials for domvanalimab-based therapies in NSCLC and gastrointestinal cancers. The interim analysis of the ARC-8 trial for quemliclustat indicates no significant safety issues, but final data on progression-free and overall survival are awaited in 2023.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, will engage in a virtual fireside chat at the 13th Annual Wedbush PacGrow Healthcare Conference. The event is scheduled for August 10, 2022, at 12:00 p.m. ET. Interested parties can access a live webcast via the Arcus Biosciences website, with a replay available post-event. Founded in 2015, Arcus is advancing six investigational medicines aimed at targeting cancer pathways.

Arcus Biosciences, Inc. (NYSE:RCUS) announced that its Compensation Committee granted options to six employees for a total of 10,200 shares at an exercise price of $26.19, the closing price on July 25, 2022. Additionally, they received restricted stock units for 5,100 shares. These equity awards were issued under the company's 2020 Inducement Plan, approved in January 2020, compliant with NYSE Listed Company Manual Rule 303A.08. Arcus is focused on developing innovative cancer therapies, advancing six investigational medicines in clinical studies.